{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-058543","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.062281+00:00","generated_at":"2026-06-25T21:07:07.174579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acurx Pharma Q1 net loss $2.7M ($0.26/shr); Phase 2b CDI trial progressing","bullets":["Cash $11.1M at March 31, 2022, down from $13.0M at Dec 31, 2021.","Net loss $2.7M vs $1.5M YoY; R&D costs rose to $0.8M from $0.1M on Phase 2b trial costs.","Phase 2b CDI trial enrollment ongoing; completion expected late H2 2022.","Protocol amended to add exploratory Extended Clinical Cure endpoint at day 56 and day 84.","Shares outstanding 10,263,202 as of March 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-058543","json":"https://secwatch.observer/filing/0001104659-22-058543.json","markdown":"https://secwatch.observer/filing/0001104659-22-058543.md","text":"https://secwatch.observer/filing/0001104659-22-058543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922058543/0001104659-22-058543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922058543/tm2214543d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:07:07.174579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}